SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom's stock is trending amid discussions around its latest earnings report, which initially sparked a rally but was followed by a sharp decline during the conference call. Community chatter revolves around potential profit-taking, analyst target adjustments, and the overall impact of AI-related revenue on the company's future growth. Some traders are also pointing to broader market trends and sector rotations as contributing factors to the stock's volatility.

Tilray Brands, Inc. engages as a consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis, Distribution, Beverage, and Wellness. The Cannabis segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage segment refers to the production, marketing, and sale of beverages. The Wellness segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Tilray Brands Inc

TLRY is trending amid speculation that the cannabis industry may benefit from potential federal policy changes, including reports of Trump considering reclassification. The community is actively discussing short squeeze potential due to low share availability and high short interest. Investors are closely watching for further developments on federal policy.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE is trending as community members rally around the revival of OG memes and the unique culture surrounding Rage Comics. Discussions focus on the community's dedication, consistent activity, and the potential for significant growth. Believers are eagerly anticipating a return to the 2021 vibes and a renewed focus on long-term conviction in the memecoin space.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is trending as community members promote its culture-focused approach within the cannabis industry, emphasizing its roots on the Solana blockchain and vision to be "like Bitcoin, but way higher". Discussions highlight the project's long-term vision alongside potential shifts in cannabis reform.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending amid community speculation about a potential buyout from a major pharmaceutical company, driven by promising data in its cancer treatment pipeline. Investors are highlighting the company's undervaluation and significant short interest, suggesting a potential short squeeze opportunity. Discussions also include the potential for strategic partnerships and upcoming catalysts, contributing to the stock's recent activity.

Keeta is a high-performance layer-1 blockchain designed to unify transactions across different blockchains and fiat payment systems, eliminating the need for costly intermediaries, reducing fees, and enabling near-instant settlements. With 400-millisecond transaction finality and the ability to process 10 million transactions per second, Keeta sets a new industry benchmark for speed and scalability.  Founded in 2022 and backed by Eric Schmidt, the former CEO of Google, Keeta has been engineered to meet the stringent regulatory and operational requirements of financial institutions. Its advanced on-chain compliance protocols, including KYC and AML, ensure security and regulatory adherence. Keeta’s architecture natively supports asset tokenization and digital identity, making it an ideal platform for stablecoins and real-world asset transfers.  By facilitating cross-chain transactions and interoperability with existing payment systems, Keeta bridges the gap between cryptocurrencies and fiat, enabling a secure, efficient, and compliant global financial ecosystem.

Keeta

Keeta is trending due to community interest in its Layer 1 blockchain, which boasts impressive transaction speeds and a compliance-first architecture, setting it apart from competitors like Polygon and Cosmos. Discussions focus on its potential to complement existing networks and its integration with traditional financial systems through partnerships like the one with Stripe's Bridge. The community also notes backing from former Google CEO Eric Schmidt as a validation of Keeta's potential, even as it remains an early-stage venture.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending due to increased investor interest, particularly around its partnerships in the defense and aerospace sectors. Community members are discussing the company's growth potential, revenue projections, and potential for a short squeeze given its low float. The stock's overnight movement and potential contracts are also sparking excitement.

lululemon athletica, Inc. engages in the business of designing, distributing, and retailing technical athletic apparel, footwear, and accessories. It operates through the following segments: Company-Operated Stores, Direct to Consumer, and Other. The company was founded by Dennis James Wilson in 1998 and is headquartered in Vancouver, Canada.

Lululemon Athletica inc.

Lululemon Athletica Inc

Lululemon is trending after beating earnings expectations, raising guidance, and announcing a CEO transition plan, which has ignited bullish sentiment. The community is discussing potential analyst upgrades and whether the stock can reach new price targets, with some pointing to strong international growth and buyback authorization as positive factors. Others express caution, citing margin concerns and the CEO's departure as potential headwinds.

Uber Technologies, Inc. is a technology platform, which engages in the development and operation of technology applications, networks, and product to power movement from point A to point B. The firm offers ride services and merchants delivery service providers for meal preparation, grocery, and other delivery services. It operates through the following segments: Mobility, Delivery, and Freight. The Mobility segment refers to products that connect consumers with Mobility Drivers who provide rides in a variety of vehicles, such as cars, auto rickshaws, motorbikes, minibuses, or taxis. The Delivery segment offers consumers the chance to search for and discover local restaurants, order a meal, and either pick-up at the restaurant or have the meal delivered. The Freight segment focuses on connecting Carriers with Shippers on its platform, and gives Carriers upfront, transparent pricing, and the ability to book a shipment. The company was founded by Oscar Salazar Gaitan, Travis Kalanick, and Garrett Camp in 2009 and is headquartered in San Francisco, CA.

Uber Technologies Inc

Uber is trending as the community discusses its potential in the robotaxi market and the impact of autonomous vehicles, especially Waymo, on its core business. Analysts remain bullish, pointing to Uber's buyback program and growth potential despite recent price target adjustments and market volatility. Community members are actively debating the stock's valuation, the achievability of future growth estimates, and if it is currently undervalued.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending as precious metals gain momentum amid speculation around potential Federal Reserve rate cuts and a weaker dollar. Community members are discussing GLD's breakout potential and its role as a safe haven asset, with some anticipating new all-time highs. The broader conversation includes comparing gold to other assets like Bitcoin, as well as analysis of technical indicators and macroeconomic factors influencing price movements.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Voss Capital LP Purchases 143,759 Shares of Actuate Therapeutics, Inc. $ACTU

Voss Capital LP grew its position in Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 101.0% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 286,140...

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

BIOS Capital Management LP Buys 71,428 Shares of Actuate Therapeutics, Inc. $ACTU

BIOS Capital Management LP raised its stake in shares of Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) by 0.7% during the 2nd quarter, according to the company in its most recent Form 13F...

What is HC Wainwright's Estimate for ACTU FY2025 Earnings?

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - Analysts at HC Wainwright boosted their FY2025 EPS estimates for shares of Actuate Therapeutics in a research report issued on Wednesday...

HC Wainwright Has Negative Forecast for ACTU FY2029 Earnings

Actuate Therapeutics, Inc. (NASDAQ:ACTU - Free Report) - HC Wainwright reduced their FY2029 EPS estimates for shares of Actuate Therapeutics in a note issued to investors on Wednesday, November 19th...

Actuate Therapeutics (NASDAQ:ACTU) Shares Up 0.5% After Better-Than-Expected Earnings

Actuate Therapeutics (NASDAQ:ACTU) Stock Price Up 0.5% Following Strong Earnings...

Actuate Therapeutics (NASDAQ:ACTU) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) announced its earnings results on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, beating analysts' consensus...

Actuate Therapeutics, Inc. (ACTU) announced on Monday that it has amended its application to the U.S. Food and Drug Administration (FDA) for its lead investigational drug Elraglusib in the treatment of pancreatic cancer.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/09/22/3153932/0/en/Actuate-Therapeutics-Provides-FDA-with-Updated-Clinical-Data-Package-to-Support-Planned-Regulatory-Interactions-with-FDA-and-EMA-Over-the-Coming-Months.html">stated</a> that it has amended the investigational new drug (IND) application with updated clinical data from its ongoing international mid-stage trial of the drug in the first-line treatment of metastatic pancreatic cancer. The study showed a statistically significant improvement in median overall survival with the combination arm of Elraglusib plus Gemcitabine/nab-paclitaxel (GnP) versus GnP alone, in addition to a 37% reduction in the risk of death.The data is intended to support planned regulatory submissions with the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) beginning later this year and continuing into early 2026, the company said. It also added that the data strengthens the case for Elraglusib as a back-bone therapy that can be combined with different regimens used to treat pancreatic cancer.The company is currently studying Elraglusib in pancreatic cancer with three ongoing trials in combination with current standards of care and novel immunotherapies.<a href="https://stocktwits.com/symbol/ACTU">ACTU shares</a> traded 6% higher at the time of writing. On Stocktwits, retail sentiment around ACTU jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:576/63;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_22_at_11_15_37_AM_png_49248344ea.webp" alt="ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits" width="576" height="63"><figcaption>ACTU's Sentiment Meter and Message Volume as of 11:15 a.m. ET on Sept. 22, 2025 | Source: Stocktwits</figcaption></figure>Actuate also stated that its recent $17.25 million public offering provides an extended runway into the second half of 2026.“We have already updated the clinical data package on file with the FDA, and during the remainder of this year and into the first quarter of 2026, we expect to gain clarity on Elraglusib’s regulatory path forward for the first-line treatment of metastatic PDAC,” said CEO Daniel Schmitt.ACTU stock is down by 11% this year but up by 6% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/tesla-stock-rallies-after-piper-sandler-hikes-price-target/chDQA76R32Z">Tesla Stock Rallies After Piper Sandler Hikes Price Target – More Details Inside</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Actuate Therapeutics Stock Rises After Updating FDA Application For Lead Investigational Drug In Treating Pancreatic Cancer

Actuate on Monday also said that its recent $17.25 million public offering provides an extended runway into the second half of 2026. 

Equity

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

Fiscal Period	Estimated	Reported	Surprise	Result
Q4 '25	-$0.26	--	--	N/A
Q3 '25	-$0.26	--	--	N/A
Q2 '25	-$0.30	-$0.30	--	EXPECTED
Q1 '25	-$0.30	--	--	N/A
Q4 '24	-$0.29	--	--	N/A

ACTU
Actuate Therapeutics Inc.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q4 '25

Historical Earnings

Latest ACTU News

ACTUActuate Therapeutics Inc.